European Stocks Trading Below Estimated Value In October 2025

Simply Wall St

As European markets navigate a landscape of steady interest rate policies and renewed trade concerns, major stock indexes like Italy’s FTSE MIB and Germany’s DAX have shown resilience with modest gains. In this context, identifying stocks that are trading below their estimated value can offer investors potential opportunities to capitalize on market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In Europe

NameCurrent PriceFair Value (Est)Discount (Est)
XTPL (WSE:XTP)PLN68.70PLN135.5649.3%
Truecaller (OM:TRUE B)SEK41.48SEK82.2749.6%
Noratis (XTRA:NUVA)€0.805€1.5648.3%
LION E-Mobility (XTRA:LMIA)€1.09€2.1449%
Lingotes Especiales (BME:LGT)€5.80€11.2648.5%
Exel Composites Oyj (HLSE:EXL1V)€0.378€0.7348.5%
Endomines Finland Oyj (HLSE:PAMPALO)€26.05€50.5348.5%
E-Globe (BIT:EGB)€0.675€1.3148.5%
Demant (CPSE:DEMANT)DKK220.20DKK429.3148.7%
Atea (OB:ATEA)NOK143.80NOK282.1449%

Click here to see the full list of 212 stocks from our Undervalued European Stocks Based On Cash Flows screener.

We'll examine a selection from our screener results.

Millenium Hospitality Real Estate SOCIMI (BME:YMHRE)

Overview: Millenium Hospitality Real Estate SOCIMI (BME:YMHRE) focuses on investing in and managing high-quality hotel properties, with a market cap of €247.51 million.

Operations: The company's revenue is primarily derived from hotel leases, generating €17.37 million, with an additional contribution of €9.02 million from other activities.

Estimated Discount To Fair Value: 47.4%

Millenium Hospitality Real Estate SOCIMI is trading at €2.14, significantly below its estimated fair value of €4.07, suggesting it may be undervalued based on cash flows. Despite becoming profitable this year and having a forecasted earnings growth of 27.6% annually, the dividend yield of 5.46% isn't well covered by earnings or free cash flows. The stock has experienced high volatility recently, and its Return on Equity is expected to remain low at 4%.

BME:YMHRE Discounted Cash Flow as at Oct 2025

SmartCraft (OB:SMCRT)

Overview: SmartCraft ASA offers software solutions tailored for the construction industry across Norway, Sweden, Finland, and the United Kingdom, with a market cap of NOK4.52 billion.

Operations: SmartCraft ASA generates revenue through its software solutions designed for the construction sector in Norway, Sweden, Finland, and the United Kingdom.

Estimated Discount To Fair Value: 27.8%

SmartCraft ASA is trading at NOK 27.3, over 20% below its estimated fair value of NOK 37.82, highlighting potential undervaluation based on cash flows. The company reported Q2 sales of NOK 140.6 million and net income of NOK 27.82 million, with earnings projected to grow significantly at an annual rate of 23.8%, outpacing the Norwegian market's growth rate. However, its forecasted Return on Equity remains modest at 14.9% in three years' time.

OB:SMCRT Discounted Cash Flow as at Oct 2025

Vitrolife (OM:VITR)

Overview: Vitrolife AB (publ) is a company that provides assisted reproduction products across Europe, the Middle East, Africa, Asia-Pacific, and the Americas with a market cap of SEK17.56 billion.

Operations: Vitrolife's revenue segments include Genetics at SEK1.46 billion, Consumables at SEK1.39 billion, and Technologies at SEK691 million.

Estimated Discount To Fair Value: 42.1%

Vitrolife AB, trading at SEK 129.7, is priced significantly below its estimated fair value of SEK 223.94, suggesting undervaluation based on cash flows. Despite a decline in Q2 sales to SEK 871 million and net income to SEK 100 million compared to the previous year, earnings are forecasted to grow substantially at an annual rate of 21.9%, surpassing Swedish market expectations. The recent EUR 300 million loan agreement underscores its strong credit profile amidst slower revenue growth projections of 6.6% annually.

OM:VITR Discounted Cash Flow as at Oct 2025

Taking Advantage

Ready To Venture Into Other Investment Styles?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Vitrolife might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com